Dual HER2 blockade with trastuzumab and lapatinib yielded good response rates in HER2-amplified, RAS wild type, treatment-refractory metastatic colorectal cancer patients, according to results of the HERACLES study.
A nivolumab/ipilimumab combination significantly improved overall survival for advanced melanoma patients.
This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma.
This video examines results of a study that found that shorter sleep duration was linked with an increased risk of death among patients with prostate cancer.
This video examines phase II results of a single-arm trial that tested checkpoint inhibition plus the IDO–pathway inhibitor indoximod in patients with melanoma.
This video reviews results of the phase II CHRONOS-1 trial, a single-arm study evaluating the investigational agent copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
In this interview we discuss the use of CTCs and circulating tumor DNA for prognosis and disease monitoring in patients with breast cancer.
The combination of an intratumoral injection of CVA21 and ipilimumab has demonstrated durable response with minimal toxicity in patients with advanced melanoma.